Your browser is no longer supported. Please, upgrade your browser.
Settings
TEVA Teva Pharmaceutical Industries Limited daily Stock Chart
TEVA [NYSE]
Teva Pharmaceutical Industries Limited
Index- P/E- EPS (ttm)-2.23 Insider Own2.70% Shs Outstand1.08B Perf Week-0.90%
Market Cap15.57B Forward P/E5.45 EPS next Y2.63 Insider Trans-0.13% Shs Float1.05B Perf Month-14.83%
Income-2302.00M PEG- EPS next Q0.57 Inst Own63.70% Short Float1.94% Perf Quarter-23.45%
Sales18.85B P/S0.83 EPS this Y87.00% Inst Trans0.04% Short Ratio1.88 Perf Half Y-35.49%
Book/sh14.28 P/B1.01 EPS next Y9.75% ROA-3.70% Target Price20.20 Perf Year-19.87%
Cash/sh1.64 P/C8.74 EPS next 5Y-6.51% ROE-16.60% 52W Range14.04 - 25.96 Perf YTD-6.87%
Dividend- P/FCF8.73 EPS past 5Y-28.50% ROI-3.20% 52W High-44.68% Beta1.33
Dividend %- Quick Ratio0.60 Sales past 5Y-1.50% Gross Margin44.00% 52W Low2.28% ATR0.44
Employees42535 Current Ratio1.00 Sales Q/Q-15.50% Oper. Margin-9.40% RSI (14)33.12 Volatility2.90% 2.92%
OptionableYes Debt/Eq1.97 EPS Q/Q77.90% Profit Margin-12.70% Rel Volume0.68 Prev Close14.22
ShortableYes LT Debt/Eq1.81 EarningsMay 15 BMO Payout- Avg Volume10.80M Price14.36
Recom2.80 SMA20-5.88% SMA50-12.37% SMA200-28.60% Volume7,339,552 Change0.98%
Mar-20-19Initiated SunTrust Hold
Mar-07-19Resumed UBS Buy $22
Mar-06-19Downgrade Morgan Stanley Overweight → Equal-Weight $17
Feb-20-19Downgrade Mizuho Buy → Neutral $25 → $18
Feb-14-19Upgrade Raymond James Mkt Perform → Outperform $22
Jan-23-19Upgrade UBS Neutral → Buy
Jan-23-19Upgrade Piper Jaffray Underweight → Neutral
Jan-03-19Upgrade BofA/Merrill Underperform → Buy
Nov-05-18Upgrade Morgan Stanley Equal-Weight → Overweight
Oct-01-18Upgrade Leerink Partners Underperform → Mkt Perform
Sep-21-18Resumed Oppenheimer Perform
Sep-17-18Upgrade BTIG Research Sell → Neutral
Sep-07-18Downgrade Credit Suisse Outperform → Neutral
Jun-27-18Reiterated Citigroup Buy $25 → $27
Mar-20-18Resumed Jefferies Hold $19
Feb-12-18Upgrade Credit Suisse Neutral → Outperform
Feb-09-18Upgrade RBC Capital Mkts Underperform → Sector Perform
Feb-09-18Downgrade Piper Jaffray Neutral → Underweight
Feb-09-18Downgrade Gabelli & Co Buy → Hold
Feb-02-18Downgrade BTIG Research Neutral → Sell $17
Apr-19-19 01:58PM  U.S. FDA approves Teva's generic nasal spray to treat opioid overdose Reuters
12:04PM  FDA approves first generic naloxone nasal spray to treat opioid overdose MarketWatch
Apr-16-19 11:41AM  Allergan Falls as Supreme Court Dismisses Restasis Litigation Zacks
Apr-11-19 10:00AM  Teva Announces Launch of a Generic Version of AndroGel® (testosterone gel) 1.62% CIII in the United States Business Wire
09:34AM  BioDelivery (BDSI) Buys US Rights to Pain Drug for $30M Zacks
08:26AM  9 High-Risk Stocks to Buy for Massive Rewards InvestorPlace
Apr-10-19 08:00AM  Teva Signs New $2.3 Billion Syndicated Revolving Credit Facility Business Wire
Apr-08-19 05:00PM  Teva to Host Conference Call to Discuss First Quarter 2019 Financial Results at 8 a.m. ET on May 2, 2019 Business Wire
09:41AM  The Zacks Analyst Blog Highlights: Pfizer, Teva, Novartis, Merck and AstraZeneca Zacks
Apr-06-19 09:41AM  Lawsuit over migraine deal could be good for Amgen, analysts say MarketWatch
Apr-05-19 10:20AM  Pharma Stock Roundup: NVS Inks Immunology Deal, PFE, TEVA Get Drug Approvals in EU Zacks
10:14AM  Novartis & Amgen in Legal Dispute Over Migraine Drug Aimovig Zacks
07:50AM  Stocks making the biggest moves premarket: Tesla, Viacom, Intel, J&J, Amazon & more CNBC
Apr-04-19 06:33PM  Oklahoma drops several claims in opioid case against J&J, Teva Reuters
06:29PM  Oklahoma drops several claims in opioid case against J&J, Teva Reuters
Apr-02-19 09:36AM  Teva's Anti-CGRP Injection Ajovy Gets Approval in Europe Zacks
Apr-01-19 09:15AM  2 Incredibly Cheap Pharma Stocks to Buy Now Motley Fool
08:08AM  Tevas AJOVY® Receives EU Approval Offering Patients the First and Only Anti-CGRP Treatment with Both Quarterly and Monthly Dosing for the Prophylaxis of Migraine in Adults Business Wire
07:02AM  BMOs Got A Point About Teva Stock, But Are Investors Willing To Listen? InvestorPlace
03:00AM  Tevas COPAXONE® 40mg Favorable Response from European Patent Office Business Wire
Mar-30-19 08:15PM  Were Hedge Funds Right About Souring On Teva Pharmaceutical (TEVA)? Insider Monkey
12:37PM  Wall Street Has Given Up on These 3 Stocks, and That's a Huge Mistake Motley Fool
Mar-28-19 11:50AM  Teva Pharmaceutical Initiated at Market Perform at BMO TheStreet.com
Mar-27-19 06:13PM  Novartis (NVS) Receives FDA Approval for MS Drug Mayzent Zacks
04:30PM  Jazz's Xyrem Follow-On Drug Succeeds in Phase III Study Zacks
Mar-26-19 02:21PM  Teva Pharmaceutical Option Bull Makes a Bold Bet Schaeffer's Investment Research
Mar-25-19 04:54PM  Oklahoma top court clears way for Purdue, J&J, Teva to face opioid trial Reuters
Mar-22-19 03:43PM  Teva Announces Launch of a Generic Version of EXJADE® (deferasirox) Tablets For Oral Suspension in the United States Business Wire
Mar-20-19 11:14AM  Jazz Pharmaceuticals' Sleep Drug NDA Awaits FDA Decision Zacks
11:10AM  AbbVie's Venclexta Multiple Myeloma Studies Put on Hold by FDA Zacks
Mar-18-19 05:50PM  Teva Pharmaceutical Industries Ltd. (TEVA) Outpaces Stock Market Gains: What You Should Know Zacks
Mar-15-19 01:51PM  After Berkshire Bought Teva Pharmaceutical Stock, Should Others Follow Suit? InvestorPlace
10:23AM  BioDelivery (BDSI) Q4 Earnings In Line, Sales Beat, Stock Up Zacks
Mar-14-19 11:01AM  Insys Plunges on Auditor's Concern About Insufficient Funds Zacks
Mar-12-19 10:20AM  Allergan Announces FDA Acceptance of Migraine Candidate NDA Zacks
06:06AM  3 Brand-Name Healthcare Stocks That Haven't Been This Cheap in a Decade Motley Fool
Mar-11-19 05:50PM  Teva Pharmaceutical Industries Ltd. (TEVA) Gains But Lags Market: What You Should Know Zacks
Mar-06-19 11:34AM  Lilly's Emgality Gets FDA Priority Review for Cluster Headache Zacks
10:00AM  Why Teva Pharmaceutical Industries Stock Sank in February Motley Fool
08:25AM  Investor Expectations to Drive Momentum within Amarin, PulteGroup, LivaNova, Teva Pharmaceutical Industries, Viad, and Activision Blizzard Discovering Underlying Factors of Influence GlobeNewswire
07:47AM  Market Direction, Big Anniversary and a GE Play: Market Recon TheStreet.com
Mar-05-19 05:05PM  FDA's Scott Gottlieb Resigns What's Next For Biotech, Pharma? Investor's Business Daily
Mar-01-19 04:08PM  Teva Announces Launch of an Authorized Generic of Flector® Patch (diclofenac epolamine topical patch) in the United States Business Wire
02:37PM  3 Life Sciences Stocks to Invest In InvestorPlace
Feb-28-19 12:31PM  Antares Pharma Inc (ATRS) Q4 2018 Earnings Conference Call Transcript Motley Fool
Feb-27-19 11:49AM  Mylan (MYL) Q4 Earnings & Revenues Miss Estimates, Stock Down Zacks
Feb-26-19 01:57PM  Corcept Therapeutics Incorporated (CORT) Q4 2018 Earnings Conference Call Transcript Motley Fool
12:15PM  America's 'inefficient' health care system is driving our fiscal instability: Powell Yahoo Finance
08:32AM  Alkermes' (ALKS) and Biogen's NDA for BIIB098 Accepted by FDA Zacks
Feb-25-19 10:28AM  Momenta (MNTA) Q4 Loss Narrower Than Expected, Revenues Beat Zacks
Feb-22-19 12:09PM  Is There An Opportunity With Teva Pharmaceutical Industries Limiteds (NYSE:TEVA) 43.61% Undervaluation? Simply Wall St.
Feb-20-19 03:09PM  Mylan (MYL) to Report Q4 Earnings: What's in the Offing? Zacks
09:08AM  Allergan Responds to Investor's Call for CEO/Chair Role Split Zacks
08:42AM  Pfizer & Lilly's Pain Candidate Succeeds in Back Pain Study Zacks
07:34AM  The Daily Biotech Pulse: Teva Settles With FTC, Setback For Merck In Liver Cancer Trial, Sienna Biopharma Offering Benzinga
05:49AM  Teva Slips After 'Pay-For-Delay' Settlement with US Federal Trade Commission TheStreet.com
Feb-19-19 07:36PM  U.S. settles with Teva over keeping generic drugs off market Reuters
06:57PM  U.S. settles with Teva over keeping generic drugs off market Reuters
06:55PM  U.S. settles with Teva over keeping generic drugs off market Reuters
06:24PM  Teva Finalizes Settlement with Federal Trade Commission to Resolve All Outstanding Litigation between the Parties Business Wire
06:07PM  U.S. settles three reverse payment fights with Teva units Reuters
09:48AM  Teva Pharmaceutical Industries Ltd (TEVA) Files 10-K for the Fiscal Year Ended on December 31, 2018 GuruFocus.com
06:00AM  Teva expects sales injection from U.S. EpiPen market Reuters
03:42AM  Teva Pharm expects about 25 pct of EpiPen market by year end Reuters
Feb-18-19 08:16AM  What's in the Cards for Amarin (AMRN) This Earnings Season? Zacks
Feb-17-19 05:08PM  Teva Pharmaceuticals CEO Talks "Trough Year", 2020 Turnaround TheStreet.com
Feb-15-19 04:37PM  Teva Pharmaceutical Finance Netherlands II BV -- Moody's announces completion of a periodic review of ratings of Teva Pharmaceutical Industries Ltd Moody's
Feb-14-19 02:28PM  Teva Pharmaceutical Industries (TEVA) Q4 2018 Earnings Conference Call Transcript Motley Fool
01:34PM  Credit Suisse Stays Sidelined On Teva: 'Our Growth Expectations Are Below That Of The Company' Benzinga
11:02AM  Where Are Teva Shares Headed After the Q4 Decline? Investopedia
08:41AM  Teva (TEVA) Q4 Earnings Miss,'19 View Weak, Shares Down Zacks
07:26AM  3 Big Stock Charts for Thursday: Conagra Brands, Intel and Franklin Resources InvestorPlace
Feb-13-19 07:28PM  [$$] King of Generics Pushes Into Biotech Drugs The Wall Street Journal -7.79%
05:46PM  Teva CEO on the pharmaceutical industry Yahoo Finance Video
05:18PM  Teva slides on forecast, drags other generic drugmakers Reuters Videos
04:49PM  3 Things to Know at Market Close: Teva, Google and Cisco TheStreet.com
04:36PM  Why Teva Pharmaceutical Industries, McDermott International, and Groupon Slumped Today Motley Fool
04:13PM  Teva Expects To Hit Bottom In 2019 Stock Dives On Lagging Outlook Investor's Business Daily
03:07PM  Key Takeaways from Eli Lilly's (LLY) Q4 Earnings Report Zacks
01:09PM  Teva Stock Falls Because 2019 Will Be a Trough Year Barrons.com
12:44PM  Teva Pharmaceutical Earnings: Why TEVA Stock Is Tanking Today InvestorPlace
12:06PM  Stocks making the biggest moves midday: Teva Pharmaceuticals, Hilton, Groupon & more CNBC
11:41AM  [$$] Teva's Turnaround Stalls Out The Wall Street Journal
11:28AM  Teva Pharmaceutical sees weaker than expected 2019, shares tumble Reuters
11:21AM  Teva Pharm sees weaker than expected 2019, shares tumble Reuters
10:59AM  Teva Investors Respond With Selloff as CEO Schultz Calls Bottom Bloomberg
10:38AM  Earnings & Data Deluge Zacks
10:28AM  Teva Stock Slips on Back of Weak 2019 Outlook; Analysts Weigh In SmarterAnalyst
10:27AM  Markets Keeping Optimistic... For Now; Plus HLT, TEVA, DISH Zacks
10:21AM  Teva CEO: "Content" with 2/3 access of payers for migraine drug Ajovy Reuters
09:34AM  Teva Pharma Tumbles as Earnings and Outlook Miss Estimates TheStreet.com
09:25AM  Teva Pharma Stock Tumbles and 4 More Wednesday Morning Movers Barrons.com
08:48AM  UPDATE: Teva stock tumbles premarket as earnings and guidance fall short of estimates MarketWatch
08:24AM  [$$] King of Generics Pushes Into Biotech Drugs The Wall Street Journal
07:43AM  Stocks making the biggest moves premarket: Hilton Worldwide, Dish Network, Deere, GM & more CNBC
07:10AM  Teva Pharm Q4 profit falls, sees weaker than expected 2019 Reuters
07:08AM  Teva Pharma Earnings Miss, Guidance Weak; Stock Dives Investor's Business Daily
07:00AM  Teva Reports Fourth Quarter and Full Year 2018 Financial Results Business Wire
Feb-10-19 02:07AM  Economic Calendar - Top 5 Things to Watch This Week Investing.com
Feb-08-19 05:50PM  Teva Pharmaceutical Industries Ltd. (TEVA) Stock Sinks As Market Gains: What You Should Know Zacks
Teva Pharmaceutical Industries Limited, a pharmaceutical company, develops, manufactures, markets, and distributes generic medicines and a portfolio of specialty medicines worldwide. It operates through two segments, Generic Medicines and Specialty Medicines. The Generic Medicines segment offers sterile products, hormones, narcotics, high-potency drugs, and cytotoxic substances in various dosage forms, including tablets, capsules, injectables, inhalants, liquids, ointments, and creams. This segment also develops, manufactures, and sells active pharmaceutical ingredients. The Specialty Medicines segment provides specialty medicines for use in central nervous system and respiratory indications. Its products in the central nervous system area comprise Copaxone for the treatment of relapsing forms of MS; and AUSTEDO for the treatment of tardive dyskinesia and chorea associated with Huntington disease. This segment's products in the respiratory market include ProAir, ProAir Respiclick, QVAR, Duoresp Spiromax, Qnasl, Braltus, Cinqair/Cinqaero, and Aerivio Spiromax for the treatment of asthma and chronic obstructive pulmonary disease, as well as Bendeka, Treanda, Granix, Trisenox, Lonquex, and Tevagrastim/Ratiograstim products in the oncology market. The company has collaboration arrangements with Otsuka Pharmaceutical Co. Ltd. and Regeneron Pharmaceuticals, Inc. Teva Pharmaceutical Industries Limited was founded in 1901 and is headquartered in Petach Tikva, Israel.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
O'Grady Brendan P.EVP, North America CommercialMar 18Sale16.631,17919,6011,388Mar 19 08:29 AM
Nazzi GianfrancoEVP, Growth Markets CommercialMar 18Sale16.643205,3269,002Mar 19 08:17 AM
Daniell RichardExec. VP, European CommercialMar 18Sale16.641,29721,5880Mar 19 08:14 AM
Stark David MatthewExec. VP Chief Legal OfficerMar 18Sale16.432,35838,7422,974Mar 19 08:11 AM
McClellan Michael JamesEVP, Chief Financial OfficerMar 18Sale16.632303,82412,760Mar 19 08:08 AM
Griffin Deborah AChief Accounting OfficerMar 18Sale16.6394315,6770Mar 19 08:06 AM
Fridriksdottir HafrunExecutive VP, Global R&DMar 18Sale16.633565,91916,750Mar 19 08:04 AM
Dethlefs SvenEVP Global Marketing&PortfolioMar 18Sale16.6363210,5079,149Mar 19 08:02 AM
Stark David MatthewExec. VP Chief Legal OfficerMar 12Sale15.822,44438,6642,974Mar 14 07:44 AM
O'Grady Brendan P.EVP, North America CommercialMar 12Sale15.6773811,5681,388Mar 14 07:41 AM
Nazzi GianfrancoEVP, Growth Markets CommercialMar 12Sale15.693255,0998,450Mar 14 07:36 AM
Griffin Deborah AChief Accounting OfficerMar 12Sale15.6795314,9380Mar 14 07:33 AM
Dethlefs SvenEVP Global Marketing&PortfolioMar 12Sale15.6764710,1428,602Mar 14 07:31 AM
Daniell RichardExec. VP, European CommercialMar 12Sale15.6971511,2180Mar 14 07:28 AM
O'Grady Brendan P.EVP, North America CommercialMar 04Sale16.881,16619,6861,388Mar 05 07:36 AM
McClellan Michael JamesEVP, Chief Financial OfficerMar 04Sale16.883636,12912,330Mar 05 07:28 AM
Griffin Deborah AChief Accounting OfficerMar 04Sale16.884,10769,3400Mar 05 07:23 AM
Fridriksdottir HafrunExecutive VP, Global R&DMar 04Sale16.884096,90516,094Mar 05 07:16 AM
Dethlefs SvenEVP Global Marketing&PortfolioMar 04Sale16.8860610,2318,058Mar 05 07:10 AM
Daniell RichardExec. VP, European CommercialMar 04Sale16.882,09835,4230Mar 05 07:05 AM
Nazzi GianfrancoEVP, Growth Markets CommercialMar 04Sale16.885128,6457,892Mar 05 08:20 AM
Stark David MatthewExec. VP Chief Legal OfficerFeb 14Sale17.743,92669,6472,974Feb 19 07:26 AM
de Notaristefani CarloExecutive VP Global OperationsFeb 14Sale17.673,19256,39918,209Feb 19 07:05 AM
Fridriksdottir HafrunExecutive VP, Global R&DFeb 14Sale17.671,84132,52915,338Feb 19 07:11 AM
de Notaristefani CarloExecutive VP Global OperationsFeb 13Sale17.885,04190,10812,121Feb 14 07:43 AM
Fridriksdottir HafrunExecutive VP, Global R&DJan 02Sale15.701,64325,79911,826Jan 03 07:24 AM
Fridriksdottir HafrunExecutive VP, Global R&DNov 30Sale21.7693320,3048,829Dec 04 08:09 AM
McClellan Michael JamesEVP, Chief Financial OfficerNov 05Sale22.733467,86511,644Nov 07 06:38 AM
Daniell RichardExec. VP, European CommercialSep 18Sale23.692,48858,9430Sep 20 04:04 PM
O'Grady Brendan P.EVP, North America CommercialSep 18Sale23.711,24129,4201,388Sep 20 04:10 PM
Nazzi GianfrancoEVP, Growth Markets CommercialSep 18Sale23.691,37932,6707,005Sep 20 04:09 PM
Griffin Deborah AChief Accounting OfficerSep 18Sale23.712,37656,3280Sep 20 04:08 PM
Dethlefs SvenEVP Global Marketing&PortfolioSep 18Sale23.7162514,8177,265Sep 20 04:06 PM
Daniell RichardExec. VP, European CommercialSep 10Sale21.2569614,7900Sep 11 04:17 PM
Codner Iris BeckEVP Global Brand&CommunicationAug 09Sale22.704,16594,5418,290Aug 13 08:34 AM
Dethlefs SvenEVP Global Marketing&PortfolioAug 03Buy21.922,00043,8406,445Aug 07 09:45 AM
MIGNONE ROBERTODirectorMay 10Buy19.32250,0004,829,7001,500,000May 11 04:15 PM
MIGNONE ROBERTODirectorMay 09Buy19.21500,0009,603,1501,250,000May 11 04:15 PM